CIK细胞过继免疫治疗晚期恶性肿瘤的临床研究

Clinical study of cytokine-induced killer cells in the treatment of patients with advanced malignant tumor after chemotherapy

目的评价化疗后行CIK细胞治疗恶性肿瘤的疗效。方法将105例病人随机分为两组，治疗组71例采用CIK细胞治疗，化疗结束后2～4周，输注CIK细胞；对照组34例单用化疗。观察指标：疗效、生存质量、毒性、无进展生存期。结果治疗组71例化疗后接受CIK细胞治疗者中，总有效率明显高于对照组，生活质量提高显著，毒性未增加，无进展生存期明显延长。结论化疗后行CIK细胞过继免疫治疗，对晚期肿瘤患者，能够改善生活质量，延长生存期。

Objective To estimate the clinical effects in the treatment of patients with advanced malignant tumor with cytokine-induced killer （CIK） cells. Methods CIK cells were induced with IL-2. γ-IFN. anti-CD3 monoclonal antibody and IL-1, then were transfused back to the patients with advanced malignant tumor after two weeks, for observation of effects,life quality, PFS, toxic reaction and the Karnofsky＇ s grade. Results The effective rate and survival period of CIK group were significantly higher than that of control group. Conclusion CIK ceils therapy can enhance effect of tile anti-cancer, improve survival quantity and prolong survival period, which probably can provide a potent immune therapeutic strategy for patients with advanced malignant tumor.